Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
**Background:** Agents targeting the prostacyclin (PGI~2~) pathway are important in managing pulmonary arterial hypertension (PAH). No head-to-head clinical trials have compared outcomes between the 3 different PGI~2~-pathway drugs most commonly available in countries with advanced healthcare: oral...
Saved in:
Main Authors: | Ci Song, Peter Kunovszki, Amélie Beaudet |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2022-06-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.35246 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
by: Piotr Kędzierski, et al.
Published: (2025-01-01) -
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
by: Richard Channick, MD, et al.
Published: (2025-02-01) -
The use of inhaled nitric oxide in newborns with persistent pulmonary hypertension
by: Cynthia Reyes Flores
Published: (2025-01-01) -
Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population
by: Andrew E. Stine, et al.
Published: (2025-01-01) -
Persistent Stapedial Artery Encountered during Cochlear Implantation
by: Holly Jones, et al.
Published: (2022-01-01)